5-hme-CTP, a nucleotide analog, has been found to selectively activate purinergic P2Y1 receptors, thereby enhancing biomedical research efforts aimed at uncovering cellular signaling pathways relevant to diverse biological phenomena such as platelet activation. Given its multifaceted role, it comes as no surprise that beyond being a great tool for scientific inquiry, 5-hme-CTP holds great potential for therapeutic interventions in diseases associated with compromised cellular function, such as stroke, multiple sclerosis, and Alzheimer's disease.
Chemical Structure:
